司美格鲁肽口服减重药已开出超60万张处方,市场空间还有多大

第一财经
Apr 06

除了礼来的竞争之外,诺和诺德面临的更大挑战在于司美格鲁肽的核心专利在包括中国在内的国家已经到期,这也令大量仿制药即将涌入这些市场。   随着越来越多的GLP-1类减重药开始走向市场,竞争也变得更加激烈。不过,在诺和诺德CEO迈克·杜斯塔尔(Mike Doustdar)看来,减重药市场规模庞大,制药行业目前仅触及“皮毛”。   在下周即将召开肥胖医学协会年会前,杜斯塔尔接受媒体采访时表示,包括...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10